RESUMEN
After an amputation, processes of change in the body image as well as a change in body scheme have direct influences on the quality of living in every patient. Within this paper, a paradigm of experimental induced body illusion (the Rubber Hand Illusion, RHI) is integrated in a prosthetic hardware simulator concept. This concept combines biodynamical and visual feedback to enhance the quality of rehabilitation and to integrate patients' needs into the development of prostheses aiming on user-centered solutions. Therefore, user-centered design parameters are deducted. Furthermore, the basic concept of the visual simulation is presented and a possibility for its implementation is given. Finally, issues and conclusions for future work are described.
Asunto(s)
Simulación por Computador , Retroalimentación Sensorial , Aparatos Ortopédicos , Diseño de Prótesis , Imagen Corporal , HumanosRESUMEN
In this paper, a novel biomechanical modeling and simulation environment with an emphasis on user-specific customization is presented. A modular modeling approach for multi-body systems allows a flexible extension by specific biomechanical modeling elements and enables an efficient application in dynamic simulation and optimization problems. A functional distribution of model description and model parameter data in combination with standardized interfaces enables a simple and reliable replacement or modification of specific functional components. The user-specific customization comprises the identification of anthropometric model parameters as well as the generation of a virtual three-dimensional character. The modeling and simulation environment is associated with Prosthesis-User-in-the-Loop, a hardware simulator concept for the design and optimization of lower limb prosthetic devices based on user experience and assessment. For a demonstration of the flexibility and capability of the modeling and simulation environment, an exemplary application in context of the hardware simulator is given.
Asunto(s)
Miembros Artificiales , Retroalimentación Fisiológica/fisiología , Marcha/fisiología , Pierna/fisiología , Modelos Biológicos , Postura/fisiología , Simulación por Computador , Femenino , Humanos , Masculino , Ajuste de Prótesis/métodos , Adulto JovenRESUMEN
In this study, we describe the successful use of a gene transfer approach to demonstrate the ability of forced BCR-ABL expression to deregulate the growth and differentiation of primitive naive human hematopoietic cells after their transplantation into immunodeficient mice. Human CD34+ cord blood cells were exposed to an MSCV retrovirus containing a BCR-ABL-IRES-GFP (P210) cassette and then injected immediately into sublethally irradiated nonobese diabetic-severe combined immunodeficiency (NOD/SCID) or NOD/SCID-beta2microglobulin-/- mice. P210- and control-transduced (GFP+) human hematopoietic cells were produced in the bone marrow of the mice at similar levels until termination of the experiments 5-6 months later. However, the P210-transduced cells produced a markedly different spectrum of progeny, with an increased ratio of myeloid to B-lymphoid cells and a frequently prolonged increase in erythroid and megakaryocytic cells. After 5 months, several of the mice transplanted with P210-transduced cells developed an increased WBC count and/or splenomegaly due to an expansion of the human GFP+ population. These findings demonstrate that forced expression of BCR-ABL in primitive transplantable human hematopoietic cells is sufficient to cause a rapid and persistent deregulation of their growth and differentiation in vivo with occasional evidence after several months of progression to an early stage of disease.
Asunto(s)
Diferenciación Celular , División Celular , Sangre Fetal/citología , Proteínas de Fusión bcr-abl/genética , Leucemia Experimental , Trasplante de Neoplasias , Animales , Antígenos CD34/inmunología , Diferenciación Celular/genética , Diferenciación Celular/inmunología , División Celular/genética , División Celular/inmunología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Proteínas de Fusión bcr-abl/inmunología , Técnicas de Transferencia de Gen , Vectores Genéticos/genética , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/inmunología , Humanos , Ratones , Ratones Endogámicos NOD , Ratones SCID , Ratones TransgénicosRESUMEN
Xenograft models of chronic phase human chronic myeloid leukemia (CML) have been difficult to develop because of the persistence of normal hematopoietic stem cells in most chronic phase CML patients and the lack of methods to selectively isolate the rarer CML stem cells. To circumvent this problem, we first identified nine patients' samples in which the long-term culture-initiating cells were predominantly leukemic and then transplanted cells from these samples into sublethally irradiated NOD/SCID and NOD/SCID-beta2microglobulin-/- mice. This resulted in the consistent and durable (>5 months) repopulation of both host genotypes with similar numbers of BCR-ABL+/Ph+ cells. The regenerated leukemic cells included an initial, transient population derived from CD34+CD38+ cells as well as more sustained populations derived from CD34+CD38- progenitors, indicative of a hierarchy of transplantable leukemic cells. Analysis of the phenotypes produced revealed a reduced output of B-lineage cells, enhanced myelopoiesis with excessive production of erythroid and megakaropoietic cells and the generation of primitive (CD34+) leukemic cells displaying an autocrine IL-3 and G-CSF phenotype, all characteristics of primary CML cells. These findings demonstrate the validity of this xenograft model of chronic phase human CML, which should enable future investigation of disease pathogenesis and new approaches to therapy.
Asunto(s)
Modelos Animales de Enfermedad , Supervivencia de Injerto , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/patología , Leucemia Experimental/patología , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Células Madre Neoplásicas/trasplante , Animales , Factor Estimulante de Colonias de Granulocitos/genética , Factor Estimulante de Colonias de Granulocitos/metabolismo , Humanos , Interleucina-3/genética , Interleucina-3/metabolismo , Ratones , Ratones Endogámicos NOD , Ratones SCID , Ratones Transgénicos , Fenotipo , Quimera por Radiación , Factores de Tiempo , Trasplante Heterólogo/métodosRESUMEN
Using the murine B16F1 melanoma, we compared a CTL- versus helper T cell (TH)-directed vaccination approach. Mice were either orally vaccinated with attenuated Salmonella typhimurium (SL) or subcutaneously with dendritic cells (DCs) loaded with gp100 peptides predicted to bind to H2-Kb/H2-Db molecules. SL were transformed with the murine gp100 cDNA (SL-gp100) or with a fusion construct of gp100 and a fragment of invariant chain cDNA (SL-gp100/Ii). Transcription of these genes in vivo has been readily observed in monocytes and DC. Retardation of B16F1 growth was more efficiently achieved by vaccination with SL-gp100 than with DC. Vaccination with SL-gp100/Ii aiming at preferential presentation by MHC II molecules provided some further improvement due to a stronger expansion of TH and CTL. The importance of help was further sustained by a prolongation of the survival time when mice concomitantly received IL2. Notably, prophylactic, compared to therapeutic, vaccination had no additional impact on survival time/rate. This was due to a striking decrease in frequencies of gp100-specific TH, CTL, and cytokine-expressing cells during tumor growth. Thus, the efficacy of vaccination was limited by tumor-induced immunosuppression. Our data demonstrate the oral route of vaccination via Salmonella as a most convenient transfer regimen and confirm the superiority of protocols aiming at preferential activation of TH.
Asunto(s)
Vacunas contra el Cáncer/administración & dosificación , Técnicas de Transferencia de Gen , Melanoma Experimental/inmunología , Glicoproteínas de Membrana/genética , Proteínas de Neoplasias/genética , Salmonella typhimurium/genética , Linfocitos T Citotóxicos/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Animales , Cartilla de ADN/química , Células Dendríticas/inmunología , Humanos , Técnicas In Vitro , Activación de Linfocitos , Melanoma Experimental/mortalidad , Ratones , Ratones Endogámicos C57BL , Reacción en Cadena de la Polimerasa , Proteínas Recombinantes de Fusión/genética , Vacunación/métodos , Antígeno gp100 del MelanomaRESUMEN
Two fusion proteins, composed of interleukin 2 (IL-2) or tumor necrosis factor (TNF) coupled to an antibody [fusion protein (FuP); IL-2-FuP or TNF-FuP], were capable of retarding growth of a human malignant melanoma in the severe combined immunodeficient mouse depending on the concomitant application of human peripheral blood leukocytes. Here we have analyzed the mechanisms that determine the therapeutic effect. Tumor-bearing severe combined immunodeficient mice received once per week an i.v. injection of HLA-matched peripheral blood leukocytes and twice per week i.v. or intratumoral injections of FUPS: Leukocyte recovery and their activation state were monitored. The number of draining lymph node cells (LNCs) and tumor-infiltrating leukocytes increased continuously, and the yield of draining LNCs was improved significantly when the FuPs were applied locally. In IL-2-FuP-treated mice, the majority of draining LNCs and tumor-infiltrating lymphocytes expressed T-cell activation markers and IL-2, thus being classified as T helper type 1 cells. These cells displayed strong proliferative activity and initiated activation of lymphokine-activated killer cells and CTLS: TNF-FuP supported activation of CTLs and of monocytes as revealed by TNF expression and cytostatic activity. Neither the antibody, nor IL-2, nor TNF, nor the mixture of antibody and cytokines exhibited the full-fledged activational potency of the FUPS: Notably, activation of immune effector mechanisms was much stronger when the FuPs were applied intratumorally. This is the first report to show that FuPs are efficient immunostimulants in vivo for native leukocytes. Although IL-2-FuP induced a T helper type 1 response with recruitment of LAK and CTL, TNF-FuP efficiently recruited and activated monocytes and, in a less pronounced manner, CTLS:
Asunto(s)
Interleucina-2/uso terapéutico , Melanoma Experimental/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/uso terapéutico , Animales , Anticuerpos/uso terapéutico , Citocinas/biosíntesis , Modelos Animales de Enfermedad , Vías de Administración de Medicamentos , Humanos , Inmunidad/efectos de los fármacos , Interleucina-2/química , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Leucocitos Mononucleares/fisiología , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Linfocitos Infiltrantes de Tumor/efectos de los fármacos , Linfocitos Infiltrantes de Tumor/fisiología , Melanoma Experimental/inmunología , Ratones , Ratones SCID , Proteínas Recombinantes de Fusión/uso terapéutico , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/química , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Application of immunocytokines [fusion proteins (FuPs)] where the cytokine has been coupled to an antibody may not produce the severe side effects frequently observed during systemic application of cytokines in cancer therapy. However, it has not been explored whether FuPs are sufficient for intratumoral activation of leukocytes or whether intratumoral versus systemic application may be of greater efficacy. Interleukin 2 (IL2) or tumor necrosis factor (TNF) coupled to an anti-epidermal growth factor receptor monoclonal antibody (IL2-FuP or TNF-FuP) were tested in SCID mice bearing a human epidermal growth factor receptor-positive melanoma transplant and being reconstituted with human HLA-matched peripheral blood leukocytes. Whole-body autoradiography revealed larger accumulation and prolonged retention of i.v. or intratumorally applied IL2-FuP or TNF-FuP compared with the antibody. Even with low doses of FuP, tumor growth was significantly retarded, with the survival time being further prolonged by the intratumoral application. Furthermore, outgrowth of the tumor was prevented in approximately 50% of mice as long as they received weekly injections of peripheral blood leukocytes concomitantly with the FuPs, which confirmed that it was the donor leukocytes activated in vivo that retarded tumor growth. An in vitro analysis revealed that the IL2-FuP supported mainly proliferation and lymphokine-activated killer cell activity, whereas TNF-FuP stimulated cytokine production and cytotoxic activity of monocytes and, to a low degree, of T cells. Both TNF-FuP and IL2-FuP significantly accumulated in the tumor, which led to retardation of tumor growth. The therapeutic effect was improved by intratumoral application. Importantly, the efficacy of both IL2-FuP and TNF-FuP depended on the induction of an immune response in vivo.
Asunto(s)
Citocinas/uso terapéutico , Neoplasias Experimentales/tratamiento farmacológico , Animales , Anticuerpos/uso terapéutico , Modelos Animales de Enfermedad , Vías de Administración de Medicamentos , Humanos , Inmunidad/efectos de los fármacos , Interleucina-2/uso terapéutico , Ratones , Ratones SCID , Neoplasias Experimentales/mortalidad , Proteínas Recombinantes de Fusión/uso terapéutico , Análisis de Supervivencia , Resultado del Tratamiento , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/uso terapéuticoRESUMEN
The adhesion molecule CD44 consists of many isoforms of which particularly CD44v7 is of major importance in hematopoietic progenitor cell homing. An increase of progenitor cells in the periphery was observed after treating mice with a CD44v7-specific antibody, concomitant with a substantially augmented marrow-repopulating ability (MRA). Because CD44v7 is expressed on a fraction of bone marrow cells (BMC) as well as on long-term bone marrow culture-derived stromal cells, we aimed to differentiate between the functional relevance of CD44v7 on either cell type by transferring CD44v7+/+ BMC into CD44v7-/- mice and vice versa. CD44v7+/+ BMC homed poorly in the bone marrow of CD44v7-/- mice and their MRA was severely impaired. CD44v7-/- BMC, instead, exhibited an improved MRA when transferred into the CD44v7+/+ host, although their MRA remained below that of CD44v7+/+ BMC. Thus, it is predominantly, but not exclusively, expression of CD44v7 on stromal cells which supports progenitor cell homing.
Asunto(s)
Movimiento Celular/fisiología , Células Madre Hematopoyéticas/citología , Receptores de Hialuranos/fisiología , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Especificidad de Anticuerpos , Células de la Médula Ósea/citología , Células de la Médula Ósea/metabolismo , Trasplante de Médula Ósea , Ensayo de Unidades Formadoras de Colonias , Movilización de Célula Madre Hematopoyética , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/metabolismo , Receptores de Hialuranos/biosíntesis , Receptores de Hialuranos/inmunología , Ratones , Ratones Noqueados , Isoformas de Proteínas , Células del Estroma/citología , Células del Estroma/metabolismoRESUMEN
OBJECTIVE: Mobilization of hematopoietic progenitor cells is achieved mainly by application of growth factors and, more recently, by blockade of adhesion. In this report, we describe the advantages of a combined treatment with granulocyte colony-stimulating factor (G-CSF) and anti-VLA4 (CD49d)/anti-CD44 as compared to treatment with the individual components. MATERIALS AND METHODS: Mobilization by intravenous injection of anti-CD44, anti-VLA4, or G-CSF was controlled in spleen and bone marrow with regard to frequencies of multipotential colony-forming unit (C-CFU), marrow repopulating ability, long-term reconstitution, recovery of myelopoiesis, and regain of immunocompetence. RESULTS: Mobilization by anti-CD44 had a strong effect on expansion of early progenitor cells in the bone marrow, while the recovery in the spleen was poor. In anti-CD49d-mobilized noncommitted and committed progenitors, progenitor expansion was less pronounced, but settlement in the spleen was quite efficient. Thus, anti-CD44 and anti-CD49d differently influenced mobilization. Accordingly, mobilization and recovery after transfer were improved by combining anti-CD44 with anti-CD49d treatment. Mobilization by G-CSF was most efficient with respect to recovery of progenitor cells in the spleen. However, when transferring G-CSF-mobilized cells, regain of immunocompetence was strongly delayed. This disadvantage could be overridden when progenitor cells were mobilized via blockade of adhesion and when expansion of these mobilized progenitor cells was supported by low-dose G-CSF only during the last 24 hours before transfer. CONCLUSION: Mobilization of pluripotent progenitor cells via antibody blockade of CD44 or CD49d or via G-CSF relies on distinct mechanisms. Therefore, the reconstitutive capacity of a transplant can be significantly improved by mobilization regimens combining antibody with low-dose G-CSF treatment.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Factor Estimulante de Colonias de Granulocitos/farmacología , Movilización de Célula Madre Hematopoyética/métodos , Células Madre Hematopoyéticas/efectos de los fármacos , Receptores de Hialuranos/inmunología , Integrinas/inmunología , Receptores Mensajeros de Linfocitos/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Trasplante de Médula Ósea , Adhesión Celular/efectos de los fármacos , Ensayo de Unidades Formadoras de Colonias , Sinergismo Farmacológico , Supervivencia de Injerto , Células Madre Hematopoyéticas/citología , Inmunocompetencia , Integrina alfa4beta1 , Integrinas/antagonistas & inhibidores , Ratones , Ratones Endogámicos BALB C , Especificidad de Órganos , Quimera por Radiación , Receptores Mensajeros de Linfocitos/antagonistas & inhibidores , Bazo/citologíaRESUMEN
Clinical success in tumor vaccination frequently does not reach expectation. Since vaccination protocols are quite variable, we used the murine renal cell carcinoma line RENCA transfected with the lacZ gene (RENCA-beta-gal) to compare the efficacy of two different vaccination strategies or their combination and to elaborate on the underlying mechanisms. BALB/c mice were vaccinated either with naked lacZ DNA or with attenuated Salmonella typhimurium transformed with lacZ DNA or with dendritic cells (DC) loaded with the beta-galactosidase protein or mice were vaccinated with both DNA and protein. Although all regimens led to a prolongation of survival time, oral vaccination with transfected S. typhimurium followed by i.v. transfer of protein-loaded DC provided the optimal schedule. In this setting, >50% of mice remained tumor free after challenge with 10 times the lethal tumor dose of RENCA-beta-gal. As explored in transfer experiments, the superior efficacy of combining DNA and protein vaccination is due to the facts that 1) optimal protection depends on both activated CD4(+) and CD8(+) cells and 2) CD8(+) CTL are most strongly activated by vaccination with transformed Salmonella, whereas vaccination with protein-loaded DC is superior for the activation of Th. The latter induced sustained activation of CTL and recruitment of nonadaptive defense mechanisms. The data demonstrate the strength of DNA vaccination, particularly by the oral route, and provide evidence that a combined treatment with protein-loaded DC can significantly increase the therapeutic efficacy.
Asunto(s)
Antineoplásicos/inmunología , Antineoplásicos/uso terapéutico , Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/uso terapéutico , Proteínas/inmunología , Proteínas/uso terapéutico , Vacunas de ADN/inmunología , Vacunas de ADN/uso terapéutico , Animales , Antineoplásicos/administración & dosificación , Vacunas contra el Cáncer/administración & dosificación , Vacunas contra el Cáncer/genética , Carcinoma de Células Renales/inmunología , Carcinoma de Células Renales/mortalidad , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/prevención & control , División Celular/genética , División Celular/inmunología , ADN Bacteriano/administración & dosificación , ADN Bacteriano/inmunología , ADN Bacteriano/uso terapéutico , Células Dendríticas/enzimología , Células Dendríticas/inmunología , Células Dendríticas/trasplante , Sinergismo Farmacológico , Inmunidad Innata/genética , Inyecciones Subcutáneas , Neoplasias Renales/inmunología , Neoplasias Renales/mortalidad , Neoplasias Renales/patología , Neoplasias Renales/prevención & control , Operón Lac/inmunología , Activación de Linfocitos/genética , Ratones , Ratones Endogámicos BALB C , Ratones SCID , Trasplante de Neoplasias , Proteínas/administración & dosificación , Salmonella typhimurium/genética , Salmonella typhimurium/inmunología , Tasa de Supervivencia , Transformación Genética , Células Tumorales Cultivadas , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genética , beta-Galactosidasa/administración & dosificación , beta-Galactosidasa/inmunología , beta-Galactosidasa/uso terapéuticoRESUMEN
Immunosuppressive features of tumour cells are a major obstacle for immunotherapy of cancer. We recently noted that RENCA cells effectively interfere with the in vivo activation of RENCA-specific T cells. To unravel the underlying mechanism, we evaluated the influence of RENCA cells on a mixed-lymphocyte/ tumour reaction as well as an allogeneic mixed-lymphocyte reaction. We observed that RENCA cells were not directly immunosuppressive. Instead, they initiated deviation of an immune response in at least two independent directions: (i) expansion of a population of NK1.1+/CD3+ cells, which was accompanied by elimination of mainly CD4+ lymphocytes, and (ii) production of a leukocyte-derived inhibitory factor. Expression of the costimulatory molecule B7.1 by RENCA cells prevented induction of anergy, while expression of MHC class II molecules prevented expansion of NK1.1+ cells, which was accompanied by a significant decrease in cell death. Hence, an unimpaired response was observed only when RENCA cells expressed B7.1 plus MHC class II molecules. Thus, even if a tumour itself is not immunosuppressive, it can induce a strong deviation of the immune response. It is concluded that the first contact between elements of the immune system and the tumour cell can confer a severe bias on immunoregulatory circuits.
Asunto(s)
Carcinoma de Células Renales/inmunología , Tolerancia Inmunológica , Neoplasias Renales/inmunología , Escape del Tumor , Animales , Antígenos/inmunología , Antígenos Ly , Antígenos de Superficie , Apoptosis , Antígeno B7-1/inmunología , Complejo CD3/inmunología , Linfocitos T CD4-Positivos/inmunología , Células Clonales , Citocinas/biosíntesis , Proteína Ligando Fas , Antígenos de Histocompatibilidad Clase II/inmunología , Isoantígenos/inmunología , Lectinas Tipo C , Activación de Linfocitos , Prueba de Cultivo Mixto de Linfocitos , Glicoproteínas de Membrana/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Subfamilia B de Receptores Similares a Lectina de Células NK , Proteínas/inmunología , Factores Supresores Inmunológicos/biosíntesis , Células Tumorales CultivadasRESUMEN
The melanoma-associated Ag glycoprotein 100 was analyzed by the T cell epitope prediction software TEPITOPE. Seven HLA-DR promiscuous peptides predicted with a stringent threshold were used to load dendritic cells (DC), and induction of a proliferative response was monitored. PBMC of all nine donors including two patients with malignant melanoma responded to at least one of the peptides. The proliferative response was defined as a Th response by the selective expansion of CD4(+) cells, up-regulation of CD25 and CD40L, and IL-2 and IFN-gamma expression. Peptide-loaded DC also initiated a T helper response in vivo (i.e., tumor growth in the SCID mouse was significantly retarded by the transfer of PBMC together with peptide-loaded DC). Because the use of the TEPITOPE program allows for a prediction of T cell epitopes; because the predicted peptides can be rapidly confirmed by inducing a Th response in the individual patient; and because application of peptide-loaded DC suffices for the in vivo activation of helper cells, vaccination with MHC class II-binding peptides of tumor-associated Ags becomes a feasible and likely powerful tool in the immunotherapy of cancer.
Asunto(s)
Activación de Linfocitos , Glicoproteínas de Membrana/inmunología , Proteínas de Neoplasias/inmunología , Fragmentos de Péptidos/inmunología , Programas Informáticos , Linfocitos T Colaboradores-Inductores/inmunología , Traslado Adoptivo , Adulto , Secuencia de Aminoácidos , Animales , Vacunas contra el Cáncer/administración & dosificación , Vacunas contra el Cáncer/inmunología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Células Dendríticas/trasplante , Epítopos de Linfocito T/inmunología , Femenino , Inhibidores de Crecimiento/administración & dosificación , Inhibidores de Crecimiento/inmunología , Humanos , Inyecciones Subcutáneas , Células K562 , Leucocitos Mononucleares/inmunología , Leucocitos Mononucleares/trasplante , Masculino , Melanoma/inmunología , Melanoma/secundario , Melanoma Experimental/inmunología , Melanoma Experimental/patología , Melanoma Experimental/prevención & control , Ratones , Ratones SCID , Persona de Mediana Edad , Datos de Secuencia Molecular , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/síntesis química , Reproducibilidad de los Resultados , Linfocitos T Colaboradores-Inductores/metabolismo , Células Tumorales Cultivadas , Antígeno gp100 del MelanomaRESUMEN
The use of anti-CD3 x antitumor bispecific Abs is an attractive and highly specific approach in cancer therapy. Recombinant Ab technology now provides powerful tools to enhance the potency of such immunotherapeutic constructs. We designed a heterodimeric diabody specific for human CD19 on B cells and CD3epsilon chain of the TCR complex. After production in Escherichia coli and purification, we analyzed its affinity, stability, and pharmacokinetics, and tested its capacity to stimulate T cell proliferation and mediate in vitro lysis of CD19+ tumor cells. The effect of the diabody on tumor growth was investigated in an in vivo model using immunodeficient mice bearing a human B cell lymphoma. The CD3 x CD19 diabody specifically interacted with both CD3- and CD19-positive cells, was able to stimulate T cell proliferation in the presence of tumor cells, and induced the lysis of CD19+ cells in the presence of activated human PBL. The lytic potential of the diabody was enhanced in the presence of an anti-CD28 mAb. In vivo experiments indicated a higher stability and longer blood retention of diabodies compared with single chain Fv fragments. Treatment of immunodeficient mice bearing B lymphoma xenografts with the diabody and preactivated human PBL efficiently inhibited tumor growth. The survival time was further prolonged by including the anti-CD28 mAb. The CD3 x CD19 diabody is a powerful tool that should facilitate the immunotherapy of minimal residual disease in patients with B cell leukemias and malignant lymphomas.
Asunto(s)
Anticuerpos Biespecíficos/farmacología , Antígenos CD19/inmunología , Linfoma de Células B/inmunología , Linfoma de Células B/terapia , Complejo Receptor-CD3 del Antígeno de Linfocito T/inmunología , Linfocitos T/trasplante , Trasplante Heterólogo/inmunología , Animales , Anticuerpos Biespecíficos/genética , Anticuerpos Biespecíficos/aislamiento & purificación , Anticuerpos Biespecíficos/farmacocinética , Antígenos CD19/genética , Antineoplásicos/aislamiento & purificación , Antineoplásicos/farmacocinética , Antineoplásicos/farmacología , Sitios de Unión de Anticuerpos , Expresión Génica/inmunología , Humanos , Células Jurkat , Masculino , Ratones , Ratones Noqueados , Trasplante de Neoplasias , Complejo Receptor-CD3 del Antígeno de Linfocito T/genética , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacología , Células Tumorales CultivadasRESUMEN
In the recently published dynamic simulation model for mesophilic digestion of sewage sludge the hydrolysis constant refers to the total dry solid content without regarding their composition. To apply these models to the digestion of municipal solid waste, the hydrolysis constants of the various fractions must be considered. The major constituents of organic waste were identified as carbohydrates, proteins and lipids. For these three constituents the hydrolysis constants for thermophilic digestion were determined. The implementation of these constants into the existing dynamic models allowed a reasonable characterization of the digestion of municipal organic waste.
Asunto(s)
Bacterias Anaerobias/metabolismo , Modelos Biológicos , Eliminación de Residuos/métodos , Aguas del Alcantarillado/microbiología , Biodegradación Ambiental , Metabolismo de los Hidratos de Carbono , Simulación por Computador , Hidrólisis , Cinética , Metabolismo de los Lípidos , Proteínas/metabolismoRESUMEN
In the second part of this two-part article, the author reviews existing standards and current international and European standardization work, which serves to highlight the need for harmonized standards for medical devices that incorporate software. The new concepts of essential performance, and safety integrity, severity, and risk levels are examined, and these present a new basis for the revision of safety standards to make them relevant to the EC Directives.
Asunto(s)
Electrónica Médica/normas , Validación de Programas de Computación , Electrónica Médica/tendencias , Seguridad de Equipos , Unión Europea , Predicción , Humanos , Industrias , RiesgoRESUMEN
1. Following the dermal application of the carbon-14 labelled broad spectrum antimycotic 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Hoe 296, Batrafen) in the form of a 1% aqueous cream to healthy human dorsal skin (penetration time: 6 h; occlusive dressing for 5 h), percutaneous absorption accounted on average for 1.3% of the dose applied. Excretion occurred via the kidney, with biological half-lives of 1.7 h. As can be seen from penetration studies of cadaverous skin, the horny layer contained the highest concentrations, with values of 2300-4500 microgram/cm3. The levels determined in the corium were still above the minimum inhibitory concentrations. These concentrations were already obtained at the first test stage (1.5 h after application) and did not change virtually at all over the longer penetration period. According to studies using histoautoradiography, ciclopirox can penetrate the skin via the epidermis and the hair follicles. When ciclopirox-14C-olamine aqueous cream was spread on the surface of fingernails, the radioactive-labelled compound penetrated right through the nail. The percutaneous absorption in dogs was higher, at 5-15% of the dose, than it was in humans. 2. After vaginal application (1 mg/kg) of ciclopirox-14C-olamine in the form of a 1% aqueous cream to bitches, between 42 and 97% of the dose (depending on the animal) was recovered in the urine and faeces, the remainder having penetrated into the tampon used to close the vagina. 3. Ciclopirox is excreted by dogs and man in the urine, primarily as a glucuronide. In humans another glucuronide with properties similar to those of the original substance was detected. Two conjugated, relatively non-polar metabolites were also present in small amounts. The metabolite patterns after oral and dermal application were similar. The binding of ciclopirox to serum proteins in humans was 96 +/- 2% in a concentration range of 0.01-11.0 microgram/ml. 4. Placental transfer was low in the rats studied. Though there was good absorption by the mother animal, the radioactivity in the foetal tissues was always lower than that of the maternal blood.